Overview

Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia

Status:
Active, not recruiting

Trial end date:
2023-11-01

Target enrollment:

Participant gender:

Summary

Our primary objective is to determine if it is feasible for SAA patients to be transplanted using non-myeloablative conditioning and post transplantation cyclophosphamide with partially HLA-mismatched donors.

Phase:

Phase 2

Details

Lead Sponsor:

Sidney Kimmel Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Treatments:

Cyclophosphamide
Fludarabine
Fludarabine phosphate
Mesna
Mycophenolate mofetil
Mycophenolic Acid
Tacrolimus
Thymoglobulin